Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $259.05 Consensus PT from Brokerages

by · The Markets Daily

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-two analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, twenty have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $261.4762.

AXSM has been the subject of several analyst reports. TD Cowen raised their target price on Axsome Therapeutics from $275.00 to $300.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. UBS Group upped their price target on Axsome Therapeutics from $251.00 to $259.00 and gave the company a “buy” rating in a research report on Friday, April 10th. HC Wainwright reissued a “buy” rating and issued a $290.00 price target on shares of Axsome Therapeutics in a research note on Wednesday, July 15th. Guggenheim raised their price objective on Axsome Therapeutics from $245.00 to $260.00 and gave the stock a “buy” rating in a research report on Monday, May 4th. Finally, Mizuho lifted their price objective on Axsome Therapeutics from $228.00 to $310.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th.

Read Our Latest Stock Report on Axsome Therapeutics

Insider Buying and Selling at Axsome Therapeutics

In other news, Director Mark Coleman sold 643 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $249.00, for a total value of $160,107.00. Following the transaction, the director owned 30,389 shares in the company, valued at approximately $7,566,861. The trade was a 2.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Susan Mahony sold 300 shares of the company’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $237.21, for a total transaction of $71,163.00. Following the completion of the sale, the director directly owned 1,129 shares in the company, valued at approximately $267,810.09. This represents a 20.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 155,852 shares of company stock worth $37,230,112. Company insiders own 20.60% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

Hedge funds have recently bought and sold shares of the company. Kemnay Advisory Services Inc. bought a new stake in Axsome Therapeutics during the fourth quarter valued at $31,000. Hollencrest Capital Management grew its holdings in Axsome Therapeutics by 400.0% during the 1st quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock worth $34,000 after acquiring an additional 160 shares during the period. Ameriflex Group Inc. bought a new position in shares of Axsome Therapeutics in the 4th quarter worth about $37,000. Advisory Services Network LLC bought a new position in shares of Axsome Therapeutics in the 3rd quarter worth about $40,000. Finally, GAMMA Investing LLC raised its position in shares of Axsome Therapeutics by 65.4% in the 4th quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock worth $49,000 after acquiring an additional 106 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics Price Performance

AXSM stock opened at $236.95 on Friday. The company has a fifty day moving average price of $238.71 and a 200-day moving average price of $199.47. The company has a market capitalization of $12.19 billion, a P/E ratio of -63.53 and a beta of 0.60. Axsome Therapeutics has a 52-week low of $96.09 and a 52-week high of $260.19. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The business had revenue of $191.20 million for the quarter, compared to analyst estimates of $191.10 million. The company’s revenue was up 57.4% compared to the same quarter last year. As a group, equities analysts expect that Axsome Therapeutics will post -2.45 EPS for the current year.

Axsome Therapeutics Company Profile

(Get Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.

Featured Articles